Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma

PURPOSE: The signal transducer and activator of transcription 3 (STAT3) signaling pathway might be a promising therapeutic target for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This study was a multicenter, open-label, non-comparative, dose escalating phase I study of OPB-111077, an oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Changhoon, Kang, Jihoon, Lim, Ho Yeong, Kim, Jee Hyun, Lee, Myung-Ah, Lee, Kyung-Hun, Kim, Tae-You, Ryoo, Baek-Yeol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473286/
https://www.ncbi.nlm.nih.gov/pubmed/29898591
http://dx.doi.org/10.4143/crt.2018.226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473286/
https://www.ncbi.nlm.nih.gov/pubmed/29898591
http://dx.doi.org/10.4143/crt.2018.226

Ejemplares similares